Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Leo Pallwein is active.

Publication


Featured researches published by Leo Pallwein.


The Journal of Urology | 2002

Comparison Of Contrast Enhanced Color Doppler Targeted Biopsy With Conventional Systematic Biopsy: Impact On Prostate Cancer Detection

F. Frauscher; Andrea Klauser; Hubert Volgger; Ethan J. Halpern; Leo Pallwein; Hannes Steiner; Antonius Schuster; Wolfgang Horninger; Hermann Rogatsch; Georg Bartsch

Purpose: We performed a prospective study to determine whether a limited biopsy approach with contrast enhanced color Doppler ultrasound targeted biopsy of the prostate would detect cancer as well as gray scale US guided systematic biopsy with a larger number of biopsy cores.Materials and Methods: We examined 230 male screening volunteers with a total prostate specific antigen of 1.25 ng./ml. or greater and free-to-total prostate specific antigen less than 18%. Two independent examiners evaluated each subject and a single investigator performed 5 or fewer contrast enhanced targeted biopsies into hypervascular regions in the peripheral zone during intravenous infusion of the US contrast agent Levovist (Schering, Berlin, Germany). Subsequently another examiner performed 10 systematic prostate biopsies. The cancer detection rates of the 2 techniques were compared.Results: Cancer was detected in 69 of the 230 patients (30%), including 56 (24.4%) by contrast enhanced targeted biopsy and in 52 (22.6%) by system...


BJUI | 2007

Real-time elastography for detecting prostate cancer: preliminary experience

Leo Pallwein; Michael Mitterberger; Peter Struve; Germar M. Pinggera; Wolfgang Horninger; Georg Bartsch; Friedrich Aigner; Andreas Lorenz; Florian Pedross; Ferdinand Frauscher

To assess the use of real‐time elastography (RTE) for detecting prostate cancer in patients scheduled for radical prostatectomy (RP), as most solid tumours differ in their consistency from the deriving tissue, and RTE might offer a new tool for cancer detection.


European Radiology | 2007

Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection

Leo Pallwein; Michael Mitterberger; Peter Struve; Wolfgang Horninger; Friedrich Aigner; Georg Bartsch; Johann Gradl; Matthias Schurich; Florian Pedross; Ferdinand Frauscher

A prospective study was performed to determine the value of sonoelastography (SE) targeted biopsy for prostate cancer (PCa) detection. A series of 230 male screening volunteers was examined. Two independent examiners evaluated each subject. One single investigator performed ≤5 SE targeted biopsies into suspicious regions in the peripheral zone only. The stiffness of the lesion was displayed by SE and color-coded from red (soft) to blue (hard). Hard lesions were considered as malignant and targeted by biopsy. Subsequently, another examiner performed ten systematic biopsies. Cancer detection rates of the two techniques were compared. Cancer was detected in 81 of the 230 patients (35%), including 68 (30%) by SE targeted biopsy and in 58 (25%) by systematic biopsy. Cancer was detected by targeted biopsy alone in 23 patients (10%) and by systematic biopsy alone in 13 patients (6%). The detection rate for SE targeted biopsy cores (12.7% or 135 of 1,109 cores) was significantly better than for systematic biopsy cores (5.6% or 130 of 2,300 cores, P < 0.001). SE targeted biopsy in a patient with cancer was 2.9-fold more likely to detect PCa than systematic biopsy. SE targeted biopsy detected more cases of PCa than systematic biopsy, with fewer than half the number of biopsy cores in this prostate-specific antigen screening population.


BJUI | 2008

Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography

Germar-Michael Pinggera; Michael Mitterberger; Eberhard Steiner; Leo Pallwein; Ferdinand Frauscher; Friedrich Aigner; Georg Bartsch; Hannes Strasser

To investigate, using transrectal colour Doppler ultrasonography, (TRCDUS) whether perfusion of the bladder and prostate is reduced in elderly patients with lower urinary tract symptoms (LUTS), common in later life, as experimental data suggest that chronic ischaemia has a key role in the development of LUTS.


The Journal of Urology | 2010

Value of Real-Time Elastography Targeted Biopsy for Prostate Cancer Detection in Men With Prostate Specific Antigen 1.25 ng/ml or Greater and 4.00 ng/ml or Less

Friedrich Aigner; Leo Pallwein; Daniel Junker; Georg Schäfer; Gregor Mikuz; Florian Pedross; Michael Mitterberger; Werner Jaschke; Ethan J. Halpern; Ferdinand Frauscher

PURPOSE We assessed the prostate cancer detection rate of real-time elastography targeted biopsy in men with total prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less. MATERIALS AND METHODS Real-time elastography using an EUB 8500 Hitachi ultrasound system (Hitachi Medical, Tokyo, Japan) was done in 94 men with a mean age of 57.4 years (range 35 to 77) with increased prostate specific antigen between 1.25 ng/ml or greater and 4.00 ng/ml or less (mean 3.20, range 1.30 to 4.00) and a free-to-total prostate specific antigen ratio of less than 18%. Real-time elastography was done to evaluate peripheral zone tissue elasticity and hard areas were defined as suspicious. Targeted biopsies with a maximum of 5 cores were done in suspicious areas, followed by 10-core systematic biopsy. We analyzed the cancer detection rate of real-time elastography and systematic biopsy. RESULTS Cancer was found in 27 of 94 patients (28.7%). Real-time elastography detected cancer in 20 patients (21.3%) and systematic biopsy detected it in 18 (19.1%). Positive cancer cores were found in real-time elastography targeted cores in 38 of 158 cases (24%) and in systematic cores in 38 of 752 (5.1%) (chi-square test p <0.0001). The cancer detection rate per core was 4.7-fold greater for targeted than for systematic biopsy. CONCLUSIONS Real-time elastography targeted biopsy allows prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4 ng/ml or less with a decreased number of cores compared with that of systematic biopsy.


BJUI | 2009

Contrast‐enhanced ultrasonography using cadence‐contrast pulse sequencing technology for targeted biopsy of the prostate

Friedrich Aigner; Leo Pallwein; Michael Mitterberger; Germar M. Pinggera; Gregor Mikuz; Wolfgang Horninger; Ferdinand Frauscher

To evaluate contrast‐enhanced ultrasonography (US) using cadence‐contrast pulse sequencing (CPS) technology, compared with systematic biopsy for detecting prostate cancer, as grey‐scale US has low sensitivity and specificity for detecting prostate cancer.


European Radiology | 2008

Ultrasound of prostate cancer: recent advances

Leo Pallwein; Michael Mitterberger; Alexandre E. Pelzer; Georg Bartsch; Hannes Strasser; Germar M. Pinggera; Friedrich Aigner; Johann Gradl; Dieter zur Nedden; Ferdinand Frauscher

Prostate cancer is the most common cancer in men. In the future, a significant further increase in the incidence of prostate cancer is expected. Therefore, improvement of prostate cancer diagnosis is a main topic of diagnostic imaging. The systematic prostate biopsy (“ten-core biopsy”) is now the “gold standard” of prostate cancer diagnosis but may miss prostate cancer. Contrast-enhanced colour Doppler ultrasound (US) and elastography are evolving methods that may dramatically change the role of US for prostate cancer diagnosis. Contrast-enhanced colour Doppler US allows for investigations of the prostate blood flow and consequently for prostate cancer visualization and therefore for targeted biopsies. Comparisons between systematic and contrast-enhanced targeted biopsies have shown that the targeted approach detects more cancers and cancers with higher Gleason scores with a reduced number of biopsy cores. Furthermore, elastography, a new US technique for the assessment of tissue elasticity has been demonstrated to be useful for the detection of prostate cancer, and may further improve prostate cancer staging. Therefore, contrast-enhanced colour Doppler US and elastography may have the potential to improve prostate cancer detection, grading and staging. However, further clinical trials will be needed to determine the promise of these new US advances.


BJUI | 2008

α-blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms

Germar-M. Pinggera; Michael Mitterberger; Leo Pallwein; Antonius Schuster; Ralf Herwig; Ferdinand Frauscher; Georg Bartsch; Hannes Strasser

To investigate whether a mechanism of action of α‐blockers on lower urinary tract symptoms (LUTS) involves improved perfusion of the LUT.


BJUI | 2007

Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder

Michael Mitterberger; Leo Pallwein; Johann Gradl; Ferdinand Frauscher; Hannes Neuwirt; Nicolai Leunhartsberger; Hannes Strasser; Georg Bartsch; Germar-Michael Pinggera

In an interesting study, authors from Austria attempted to elucidate how often detrusor overactivity persists after TURP, and if perfusion of the lower urinary tract influences the outcome. They found that increased vascular resistance of the bladder vessels leads to reduced perfusion, and provide a possible explanation for the persistent symptoms.


BJUI | 2006

Atherosclerosis as a risk factor for benign prostatic hyperplasia

Andreas P. Berger; Georg Bartsch; Martina Deibl; Hannes Alber; Otmar Pachinger; Gernot Fritsche; Barbara Rantner; Gustav Fraedrich; Leo Pallwein; Fritz Aigner; Wolfgang Horninger; Ferdinand Frauscher

To evaluate the relationship between clinical benign prostatic hyperplasia (BPH) and atherosclerosis, using colour Doppler ultrasonography (CDUS) and symptom scores.

Collaboration


Dive into the Leo Pallwein's collaboration.

Top Co-Authors

Avatar

Georg Bartsch

Innsbruck Medical University

View shared research outputs
Top Co-Authors

Avatar

Ferdinand Frauscher

Innsbruck Medical University

View shared research outputs
Top Co-Authors

Avatar

Michael Mitterberger

Innsbruck Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Friedrich Aigner

Innsbruck Medical University

View shared research outputs
Top Co-Authors

Avatar

Wolfgang Horninger

Innsbruck Medical University

View shared research outputs
Top Co-Authors

Avatar

Johann Gradl

Innsbruck Medical University

View shared research outputs
Top Co-Authors

Avatar

F. Frauscher

Thomas Jefferson University

View shared research outputs
Top Co-Authors

Avatar

Alexandre E. Pelzer

Innsbruck Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge